Food-drug Interactions Could be Impactful for Some Lung Cancer Patients According to New Study in JNCCN

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Food-drug Interactions Could be Impactful for Some Lung Cancer Patients According to New Study in JNCCN

header-info

Jun, 14, 2023

According to new research, the administration of alectinib with a full breakfast or lunch results in higher drug concentrations when compared to administration with a low-fat breakfast across a cohort of 20 randomized patients with advanced lung cancer.

Access the full article to read more here.